Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention

Heart

Volumn 91, Issue SUPPL. 3, 2005, Pages

  Kelly, Robert V ^a   Steinhubl, S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; FORECASTING; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 20044382143     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.058511     Document Type: Review

References (27)

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerosis obstruction. Description of a new technique and a preliminary report of its application. Circ 1964;30:654-70.
2. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis. N Engl J Med 1979;301:61-8.
3. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9.
4. White GH, Liew SC, Waugh RC, et al. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg 1995;21:270-9; discussion 279-81.
5. Steinhubl S, Berger P. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? Am Heart J 2003;145:971-8.
6. Steinhubl SR, Topol EJ. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. J Thromb Thrombolysis 1999;7:227-31.
7. Moore SA, Steinhubl SR. Clopidogrel and coronary stenting: what is the next question? J Thromb Thrombolysis 2000;10:121-6.
8. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
9. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine and clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
10. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998;32:1366-70.
11. Mehta SR, Yusuf S, Peters RJ, et al. Effects of prefreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
12. Steinhubl SR, Berger PB, Mann JT 3rd, et al. arly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
13. Steinhubl SR, Darrah S, Berger P, et al. Optimal duration of pretreatment with clopidogrel prior to PCI: data from CREDO. Circulation 2003;108:17 abstract suppl IV-374.
14. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-3.
15. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-8.
16. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
17. Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG investigators. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation of PTCA to improve long-term outcome with abciximab GPIIb/IIIa receptor blockade. J Am Coll Cardiol 1998;32:1619-23.
18. Topol EJ. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2003;41(4 suppl S):S123-9.
19. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71.
20. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002;106:3063-7.
21. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
22. Armstrong PW. Heparin in acute coronary disease-requiem for a heavyweight? N Engl J Med 1997;337:492-4.
23. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results or the national investigators collaborating on enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-34.
24. Chaussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-50.
25. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
26. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischemic heart disease. Platelets 2002;13:407-13.
27. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:15-28.